| human | Q5 |
| P13049 | DDB person (GND) ID | 124689698 |
| P6178 | Dimensions author ID | 0626332151.90 |
| P227 | GND ID | 124689698 |
| P2798 | Loop ID | 530299 |
| P496 | ORCID iD | 0000-0002-4070-9976 |
| P3829 | Publons author ID | 2588224 |
| P1053 | ResearcherID | B-8799-2009 |
| M-5237-2013 | ||
| P1153 | Scopus author ID | 7005788430 |
| P4012 | Semantic Scholar author ID | 144066387 |
| P214 | VIAF ID | 55087422 |
| P108 | employer | Stanford University | Q41506 |
| Johannes Gutenberg University Mainz | Q161982 | ||
| Charité | Q162684 | ||
| P734 | family name | Metz | Q16876893 |
| Metz | Q16876893 | ||
| Metz | Q16876893 | ||
| P735 | given name | Martin | Q18002399 |
| Martin | Q18002399 | ||
| P106 | occupation | physician | Q39631 |
| P21 | sex or gender | male | Q6581097 |
| Q56984047 | 041 Prevalence, characteristics and burden of pruritus in chronic dermatoses |
| Q56984058 | 057 The role of substance P and its receptor NK1R in chronic prurigo: Results from a randomized, controlled trial with topical aprepitant |
| Q56984329 | A Role for Bax in the Regulation of Apoptosis in Mouse Mast Cells |
| Q34182028 | A beneficial role for immunoglobulin E in host defense against honeybee venom |
| Q54336903 | A novel method to generate and culture human mast cells: Peripheral CD34+ stem cell-derived mast cells (PSCMCs). |
| Q52848300 | A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. |
| Q34694547 | Acquired cold urticaria symptoms can be safely prevented by ebastine. |
| Q56984074 | Aktuelles zur kutanen Neurobiologie von Pruritus |
| Q44139353 | Anaphylaxis caused by mosquito allergy in systemic mastocytosis |
| Q56962717 | Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria |
| Q47921944 | Anti-pruritic Effect of Sertaconazole 2% Cream in Atopic Dermatitis Subjects: A Prospective, Randomized, Double-blind, Vehicle-controlled, Multi-centre Clinical Trial of Efficacy, Safety and Local Tolerability |
| Q43013007 | Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy |
| Q91087818 | Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU) |
| Q91052426 | Are we facing a change in the treatment of chronic pruritus? |
| Q56960651 | Autoimmune chronic spontaneous urticaria: What we know and what we do not know |
| Q56984267 | Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo-Controlled Trial |
| Q56984297 | Autoreaktive Urtikaria und Autoimmunurtikaria |
| Q128650206 | Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial |
| Q50027346 | Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria |
| Q52806678 | Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. |
| Q50229784 | Best practices, new perspectives and the perfect emollient: optimizing the management of contact dermatitis |
| Q92661376 | Characterization of cowhage-induced pruritus in inflamed and non-inflamed skin |
| Q104474477 | Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction |
| Q38131810 | Chronic pruritus associated with dermatologic disease in infancy and childhood: update from an interdisciplinary group of dermatologists and pediatricians |
| Q37789400 | Chronic pruritus – pathogenesis, clinical aspects and treatment |
| Q48567207 | Chronic spontaneous urticaria: how to assess quality of life in patients receiving treatment |
| Q56657510 | Chronische Urtikaria |
| Q91082778 | Chymase-Cre; Mcl-1fl/fl Mice Exhibit Reduced Numbers of Mucosal Mast Cells |
| Q33588223 | Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin |
| Q39240629 | Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review |
| Q38620912 | Comparison and Interpretability of the available Urticaria Activity Scores. |
| Q92749449 | Comparison of pruritus and sensory qualities induced by capsaicin, histamine and cowhage |
| Q41952943 | Control of Pseudomonas aeruginosa skin infections in mice is mast cell-dependent |
| Q39793293 | Critical role of IL-10 in the induction of low zone tolerance to contact allergens |
| Q56984304 | Critical role of IL-10 in the induction of low zone tolerance to contact allergens |
| Q52854220 | Definition, aims, and implementation of GA(2) LEN Urticaria Centers of Reference and Excellence. |
| Q91574219 | Definition, aims, and implementation of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence |
| Q129755061 | Development and Validation of a Patient-Reported Outcome Measure to Assess Disease Control in Chronic Prurigo |
| Q33606791 | Development and Validation of a Questionnaire for the Assessment of Pelvic Floor Disorders and Their Risk Factors During Pregnancy and Post Partum |
| Q39565260 | Development and construct validation of the angioedema quality of life questionnaire |
| Q52879396 | Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. |
| Q91795027 | Development of the Angioedema Control Test-A patient-reported outcome measure that assesses disease control in patients with recurrent angioedema |
| Q39371919 | Development, validation, and initial results of the Angioedema Activity Score |
| Q46798966 | Diagnosis and therapy of chronic urticaria-what is expected from the revision and update of the international guidelines? A report of the public consensus conference "URTICARIA 2012" |
| Q92130175 | Diagnosis and treatment of chronic inducible urticaria |
| Q46125161 | Differential effects of skin nerves on allergic skin inflammation |
| Q52974629 | Distinct roles for nerve growth factor and brain-derived neurotrophic factor in controlling the rate of hair follicle morphogenesis. |
| Q92981802 | Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review |
| Q38600600 | EADV European Prurigo Project: Expert Consensus on the Definition, Classification and Terminology of Chronic Prurigo. |
| Q56984310 | Early macrophage influx to sites of cutaneous granuloma formation is dependent on MIP-1alpha /beta released from neutrophils recruited by mast cell-derived TNFalpha |
| Q47790656 | Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial |
| Q44738836 | Effective control of recalcitrant pruritus by bevacizumab: a possible role for vascular endothelial growth factor in chronic itch? |
| Q91438081 | Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab |
| Q93074581 | Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab |
| Q56962722 | Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab |
| Q97879268 | Effective treatment with mepolizumab in a patient with refractory Wells syndrome |
| Q34570242 | Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses |
| Q44153440 | Effects of antihistamines on innate immune responses to severe bacterial infection in mice |
| Q40082741 | Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study |
| Q50957399 | Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study |
| Q128684652 | Efficacy of Remibrutinib in Patients With Chronic Spontaneous Urticaria With or Without Prior Exposure to Biologics in the Phase 3 REMIX-1 and REMIX-2 Studies |
| Q93029359 | Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment |
| Q56984161 | Erfassung von Pruritus – aktuelle Standards und Implikationen für die Praxis |
| Q97879273 | Erfolgreiche Behandlung mit Mepolizumab bei einem Patienten mit therapieresistentem Wells-Syndrom |
| Q42368789 | Erratum to: Looking forward to new targeted treatments for chronic spontaneous urticaria |
| Q56984170 | Erratum zu: Erfassung von Pruritus: aktuelle Standards und Implikationen für die Praxis |
| Q56984189 | Evidence for Non-Allergic Mast Cell Activation in Pollen-Associated Inflammation |
| Q43189139 | Evidence that the endothelin A receptor can enhance IgE-dependent anaphylaxis in mice. |
| Q48517427 | Executive summary: Methods and evidence report for the evidence - and consensus- based (S3) Guideline for the definition, classification, diagnosis, and management of urticaria - revision and update 2017. |
| Q56984127 | Fasciola hepatica Tegumental Coat Impairs Mast Cells' Ability To Drive Th1 Immune Responses |
| Q56984215 | Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria |
| Q50436226 | Galactose-α-1,3-Galactose Allergy Is Not a Hitherto Unrecognized Cause of Chronic Spontaneous Urticaria |
| Q44111099 | German version of ItchyQoL: validation and initial clinical findings |
| Q91306067 | H1-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria |
| Q48666224 | High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria |
| Q45235989 | Histamine, TNF, C5a, IL-6, -9, -18, -31, -33, TSLP, neopterin, and VEGF are not elevated in chronic spontaneous urticaria |
| Q56956631 | Human Mast Cell Tryptase Is a Potential Treatment for Snakebite Envenoming Across Multiple Snake Species |
| Q54437625 | IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities. |
| Q39498874 | IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression |
| Q56984109 | IgE Antibodies and FcεRI Are Critical For Acquired Resistance Against Honeybee Venom In Mice |
| Q33885869 | IgE mediated autoallergy against thyroid peroxidase--a novel pathomechanism of chronic spontaneous urticaria? |
| Q52804420 | Immunoglobulin E-Mediated Autoimmunity. |
| Q50075235 | In chronic spontaneous urticaria, high numbers of dermal endothelial cells, but not mast cells, are linked to recurrent angio-oedema |
| Q50926952 | Increased angiogenesis and VEGF expression correlates with disease severity in prurigo patients |
| Q41090234 | Inflammatory murine skin responses to UV-B light are partially dependent on endothelin-1 and mast cells |
| Q37614641 | Innate immunity and allergy in the skin |
| Q52881764 | Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. |
| Q38941795 | Itch Management: Topical Agents |
| Q56962731 | Kälteinduzierte Quaddeln und Angioödeme |
| Q90438284 | Ligelizumab for Chronic Spontaneous Urticaria |
| Q89548428 | Ligelizumab for Chronic Spontaneous Urticaria. Reply |
| Q38771632 | Looking forward to new targeted treatments for chronic spontaneous urticaria |
| Q128684702 | MRGPRX2 Small Molecule Antagonists Potently Inhibit Agonist-Induced Skin Mast Cell Degranulation |
| Q38151975 | Magistral formulations and pruritus therapy - What is established, what is confirmed, what is new? |
| Q56984137 | Magistral formulations and pruritus therapy - What is established, what is confirmed, what is new? |
| Q90380738 | Management of urticarial vasculitis: A worldwide physician perspective |
| Q100724956 | Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies |
| Q48250644 | Mast Cells Limit the Exacerbation of Chronic Allergic Contact Dermatitis in Response to Repeated Allergen Exposure |
| Q35370039 | Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice |
| Q37136142 | Mast cell functions in the innate skin immune system |
| Q56966657 | Mast cell-mediated reactions in vivo |
| Q90240746 | Mast cells are critical for controlling the bacterial burden and the healing of infected wounds |
| Q46701587 | Mast cells are critical for the limitation of thrombin-induced skin inflammation |
| Q93369526 | Mast cells as protectors of health |
| Q34551900 | Mast cells can enhance resistance to snake and honeybee venoms |
| Q56984177 | Mast cells cultured from IL-3-treated mice show impaired responses to bacterial antigen stimulation |
| Q52916937 | Mast cells determine the magnitude of bacterial toxin-induced skin inflammation. |
| Q36819950 | Mast cells in the promotion and limitation of chronic inflammation. |
| Q35921836 | Mast cells orchestrate type 2 immunity to helminths through regulation of tissue-derived cytokines |
| Q34367607 | Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. |
| Q45264151 | Mast cells protect from post-traumatic brain inflammation by the mast cell-specific chymase mouse mast cell protease-4. |
| Q43974973 | Mast cells protect from post-traumatic spinal cord damage in mice by degrading inflammation-associated cytokines via mouse mast cell protease 4. |
| Q52880091 | Mast cells protect from skin tumor development and limit tumor growth during cutaneous de novo carcinogenesis in a Kit-dependent mouse model. |
| Q36586548 | Mast cells rescue implantation defects caused by c-kit deficiency. |
| Q56984253 | Mast cells, basophils and mastocytosis |
| Q36776875 | Mast cells--key effector cells in immune responses |
| Q92074196 | Mast cells: Promoters of health and modulators of disease |
| Q37529040 | Mast cells: makers and breakers of allergic inflammation |
| Q56984247 | Mast cell–driven skin inflammation is impaired in the absence of sensory nerves |
| Q47859096 | Membrane-bound stem cell factor is the major but not only driver of fibroblast-induced murine skin mast cell differentiation |
| Q38217720 | Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria |
| Q37989998 | Miltefosine: a novel treatment option for mast cell-mediated diseases |
| Q47971946 | Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands |
| Q56984144 | Neue Therapeutika beim Hereditären Angioödem unbeantwortete Fragen beim Hereditären Angioödem |
| Q33866102 | Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis |
| Q42461474 | Neurotrophin-3 regulates mast cell functions in neonatal mouse skin |
| Q40004050 | Non-pathogenic commensal Escherichia coli bacteria can inhibit degranulation of mast cells |
| Q52805365 | Nutzen von Mepolizumab bei einer Patientin mit chronischer spontaner Urtikaria. |
| Q130200933 | Omalizumab Improves Angioedema-Related Quality of Life Impariment in Patients with Chronic Idiopathic/Chronic Spontaneous Urticaria: Results from the X-Act Study |
| Q94955259 | Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence |
| Q38024238 | Omalizumab in chronic urticaria |
| Q39220250 | Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis |
| Q52840117 | Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. |
| Q52840120 | Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. |
| Q38254504 | Omalizumab may not inhibit mast cell and basophil activation in vitro |
| Q56961833 | Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: a randomized, double-blind, placebo-controlled study |
| Q47731684 | Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data |
| Q38656712 | Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence |
| Q56984152 | Pathomechanismus von Angioödemen |
| Q37902833 | Pathophysiology of itch and new treatments |
| Q56984225 | Patients with chronic urticaria exhibit increased rates of sensitisation toCandida albicans, but not to common moulds |
| Q51583385 | Peltier effect-based temperature challenge: an improved method for diagnosing cold urticaria. |
| Q47807299 | Polidocanol inhibits cowhage - but not histamine-induced itch in humans |
| Q39031713 | Potential blood biomarkers in chronic spontaneous urticaria |
| Q45347035 | Practical algorithm for diagnosing patients with recurrent wheals or angioedema |
| Q56984230 | Prevalence and relevance of skin autoreactivity in chronic urticaria |
| Q46073562 | Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. |
| Q90736802 | Pruritus and sleep disturbances in patients with psoriasis |
| Q37830761 | Pruritus: an overview of current concepts |
| Q50948117 | Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity |
| Q57480237 | Real life treatment of Cholinergic Urticaria with Omalizumab |
| Q56960644 | Reply |
| Q56984238 | Reply |
| Q52837975 | Responsiveness and minimal important difference of the urticaria control test. |
| Q56984337 | Retardation of Hair Follicle Development by the Deletion of TrkC, High-Affinity Neurotrophin-3 Receptor |
| Q50727804 | Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria |
| Q51164467 | Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria |
| Q56444281 | Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria |
| Q38019500 | Role and relevance of mast cells in fungal infections |
| Q50275633 | Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant |
| Q43167471 | Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. |
| Q37821491 | Rupatadine for the treatment of allergic rhinitis and urticaria |
| Q46691003 | Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial |
| Q36359983 | Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients' Quality of Life: a Prospective, Non-interventional Trial |
| Q47759075 | S2k Guidelines for the diagnosis and treatment of chronic pruritus - update - short version |
| Q92509716 | Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial |
| Q51067258 | Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria |
| Q56983987 | Severe contact dermatitis caused by urushiol in Japanese lacquer |
| Q92898246 | Skin Barrier Damage and Itch: Review of Mechanisms, Topical Management and Future Directions |
| Q56984283 | Skin mast cells control T cell-dependent host defense in Leishmania major infections |
| Q53059424 | Skin provocation tests may help to diagnose atopic dermatitis. |
| Q47873771 | Substance P is upregulated in the serum of patients with chronic spontaneous urticaria. |
| Q28264284 | Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy |
| Q43275815 | Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant |
| Q56984210 | Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant |
| Q34858119 | Successful treatment of solar urticaria with anti-immunoglobulin E therapy |
| Q38732376 | T cell killing by tolerogenic dendritic cells protects mice from allergy |
| Q56984288 | TLR3-induced activation of mast cells modulates CD8+ T-cell recruitment |
| Q128817871 | Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial |
| Q56984093 | The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update |
| Q48517489 | The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update |
| Q50058577 | The Urticaria Activity Score-Validity, Reliability, and Responsiveness. |
| Q37605896 | The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations |
| Q52854801 | The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. |
| Q43444597 | The effects of Fasciola hepatica tegumental antigens on mast cell function |
| Q38221816 | The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria |
| Q91399811 | The response to treatment in chronic spontaneous urticaria depends on how it is measured |
| Q50069029 | The role and relevance of mast cells in urticaria |
| Q90732297 | The role of eosinophils in chronic spontaneous urticaria |
| Q38034022 | The role of interleukin-1 in allergy-related disorders |
| Q36307960 | The status quo and quo vadis of mast cells |
| Q42936833 | Therapeutic alternatives for antihistamine-refractory urticaria |
| Q56964952 | Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab |
| Q56984200 | Treatment of notalgia paraesthetica with an 8% capsaicin patch |
| Q91924043 | Treatments for chronic pruritus outside of the box |
| Q56984099 | Une réponse allergique pour lutter contre les venins |
| Q56962692 | Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A real-life study |
| Q90734618 | Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020 |
| Q90337557 | Validation of the Angioedema Control Test (AECT)-A Patient-Reported Outcome Instrument for Assessing Angioedema Control |
| Q56984273 | Viewpoint 5 |
| Q56984323 | What is the physiological function of mast cells? |
| Q36604434 | Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes? |
| Q56984084 | Wytyczne EAACI/GA2LEN/EDF/WAO dotyczące definicji, klasyfikacji, rozpoznawania i leczenia pokrzywki: weryfikacja z 2013 roku z poprawkami |
| Q46017061 | [Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series]. |
| Q97532326 | [Therapy for chronic pruritus-light at the end of a long tunnel?] |
Search more.